Aethlon Medical, Inc. (AEMD)
Stock Price:
$1.53 USD
-0.02 (-1.29%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $1.55 +0.02 (1.31%) Oct 21, 5:36 PM
Key Info
| Market Cap |
18.47M |
| Revenue (ttm) |
620,187 |
| Net Income (ttm) |
-5.72M |
| Shares Out |
12.07M |
| EPS (ttm) |
-1.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$1.53 |
| Previous Close |
$1.55 |
| Change ($) |
-0.02 |
| Change (%) |
-1.29% |
| Day's Open |
1.55 |
| Day's Range |
1.51 - 1.60 |
| Day's Volume |
171,033 |
| 52-Week Range |
0.76 - 5.02 |
More Stats
| Market Cap |
18.47M |
| Enterprise Value |
2.75M |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.07M |
| Float |
11.72M |
| EPS (basic) |
-1.07 |
| EPS (diluted) |
-1.04 |
| FCF / Share |
-0.54 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
408,508 |
| Short Ratio |
1.95 |
| Short % of Float |
3.49% |
| Beta |
0.35 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
29.78 |
| PB Ratio |
1.25 |
| Revenue |
620,187 |
| Operating Income |
-5.77M |
| Net Income |
-5.72M |
| Free Cash Flow |
-5.22M |
| Net Cash |
15.72M |
| Net Cash / Share |
1.30 |
| Gross Margin |
104.84% |
| Operating Margin |
-931.04% |
| Profit Margin |
-921.90% |
| FCF Margin |
-841.76% |
| ROA |
-37.28% |
| ROE |
-70.64% |
| ROIC |
1,323.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
9.00
Current: $1.53
High
9.00
Target: 9.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.65 | 0.23 | 0.15 | 0.39 | 0.89 | 0.76 | 1.62 | 1.23 | 1.36 | - |
| Revenue Growth | 183.15% | 53.47% | -61.84% | -55.78% | 16.28% | -53.05% | 32.01% | -9.53% | - | - |
| Gross Profit | 0.65 | 0.23 | 0.15 | 0.39 | 0.89 | 0.76 | 1.62 | 1.23 | 1.36 | - |
| Operating Income | -5.93 | -6.00 | -4.83 | -6.10 | -4.38 | -3.99 | -3.06 | -3.58 | -3.11 | -4.56 |
| Net Income | -6.37 | -6.19 | -5.68 | -7.28 | -4.87 | -6.80 | -13.36 | -4.89 | -8.11 | -5.71 |
| Shares Outstanding | 3.41 | 1.21 | 0.82 | 0.52 | 0.49 | 0.37 | 0.26 | 0.20 | 0.14 | 0.09 |
| Earnings Per Share | -1.87 | -5.13 | -6.90 | -14.10 | -9.90 | -18.30 | -51.60 | -22.50 | -60.00 | -60.00 |
| Operating Cash Flow | -5.20 | -4.29 | -3.91 | -3.51 | -4.33 | -5.05 | -2.14 | -2.10 | -1.84 | -1.97 |
| Capital Expenditures | -0.15 | - | -0.02 | -0.02 | -0.01 | - | -0.10 | - | - | - |
| Free Cash Flow | -5.35 | -4.29 | -3.94 | -3.52 | -4.34 | -5.05 | -2.24 | -2.10 | -1.84 | -1.97 |
| Cash & Equivalents | 9.62 | 3.84 | 6.99 | 1.57 | 2.15 | 0.86 | 1.25 | 0.13 | 0.15 | 0.22 |
| Total Debt | 0.04 | 0.96 | 0.84 | 0.52 | 0.50 | 0.16 | 2.53 | 2.69 | 3.66 | 2.37 |
| Net Cash / Debt | 9.57 | 2.88 | 6.15 | 1.06 | 1.65 | 0.70 | -1.28 | -2.56 | -3.51 | -2.15 |
| Assets | 10.39 | 4.12 | 7.35 | 1.73 | 2.53 | 1.38 | 1.70 | 0.50 | 0.84 | 0.57 |
| Liabilities | 1.11 | 1.82 | 1.32 | 1.13 | 1.03 | 0.73 | 16.43 | 9.64 | 10.13 | 6.54 |
| Book Value | 9.41 | 2.43 | 6.13 | 0.68 | 1.55 | 0.62 | -14.95 | -9.14 | -9.30 | -5.98 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aethlon Medical, Inc. |
| Country |
United States |
| Employees |
8 |
| CEO |
Timothy C. Rodell |
Stock Information
| Ticker Symbol |
AEMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: AEMD |
Description
Aethlon Medical, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.